Soumya Sundara Rajan

Center for Cancer Research — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

7h-index220citations118works0.22yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Research and Treatments(43), Cell Adhesion Molecules Research(42), Lung Cancer Treatments and Mutations(37), Vascular Tumors and Angiosarcomas(31), PARP inhibition in cancer therapy(20)

Publications118 total

Abstract IA004: Biocondensates in action: The formation and reformation of EWSR1, FUS and TAF15 ribonucleoprotein networks

Cancer Research·2026

HNRNPH1-mediated splicing events regulate <i>EIF4G1</i> transcript variant composition and the organization of the <i>AURKA</i> 5’UTR

2025Open Access

Abstract A001: HNRNPH1 regulates the alternative splicing of transcripts expressed by cancer-associated genes

Molecular Cancer Therapeutics·2024

Abstract A004 The ETS1-driven expression of TNS3 in Ewing sarcoma cells enhances the formation of the focal adhesions that promote cell movement

Cancer Research·2024

Abstract A016 EWSR1 in Ewing sarcoma cells exhibits enhanced recruitment to sites of active transcription compared to that observed in non-Ewing sarcoma cells

Cancer Research·2024

Supplemental Figure S8 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma

2024Open Access

Supplemental Figure S9 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma

2024Open Access

Supplemental Table S1 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma

2024Open Access

Supplemental Figure S2 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma

2024Open Access

Data from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma

2024Open Access

Supplemental Figure S6 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma

2024Open Access

Supplemental Figure S4 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma

2024Open Access

Supplemental Figure S7 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma

2024Open Access

Supplemental Figure S6 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma

2024Open Access

Supplemental Figure S4 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma

2024Open Access

Supplemental Figure S9 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma

2024Open Access

Supplemental Figure S10 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma

2024Open Access

Data from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma

2024Open Access

Supplemental Table S2 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma

2024Open Access

Supplemental Figure S8 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma

2024Open Access

page 1 of 6Next →

Frequent Co-authors

Natasha J. Caplen(25), Amit Dipak Amin(15), Jonathan H. Schatz(15), Katelyn R. Ludwig(14), Vernon Justice Ebegboni(12), Matthew J. Groysman(10), Tayvia Brownmiller(10), Patrick X. Zhao(10), Erica C. Pehrsson(10), Victor J. Collins(10), Ariana E. Nelson(10), Choh Yeung(10), Ksenia Vulikh(10), Kristine A. Isanogle(10), Arnulfo Mendoza(10), Simone Difilippantonio(10), Baktiar Karim(10), Christine M. Heske(10), Praechompoo Pongtornpipat(9), Soham D. Puvvada(9)